CAR-T cell therapy for lymphoma

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 165-183

  Ramos, Carlos A ^a   Heslop, Helen E ^a   Brenner, Malcolm K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adoptive T cell therapy; CD19; CD20; CD30; Immunotherapy; Kappa light chain

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; EPITOPE; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIBODY COMBINING SITE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; HODGKIN DISEASE; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOID TISSUE; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHODGKIN LYMPHOMA; PATIENT SAFETY; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; GENE TRANSFER; GENETICS; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN; PROCEDURES; TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; EPITOPES; GENE TRANSFER TECHNIQUES; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, NON-HODGKIN; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84954526563     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051914-021702     Document Type: Article

References (93)

1. Weinstock DM, Dalla-Favera R, Gascoyne RD, et al. (2015). A roadmap for discovery and translation in lymphoma. Blood 125: 2175-77
2. Kuppers R, Engert A, Hansmann ML. (2012). Hodgkin lymphoma. J. Clin. Invest. 122: 3439-47
3. Schuster SJ, Neelapu SS, Gause BL, et al. (2011). Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29: 2787-94
4. Bollard CM, Gottschalk S, Torrano V, et al. (2014). Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol. 32: 798-808
5. Heslop HE, Slobod KS, Pule MA, et al. (2010). Long-Term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115: 925-35
6. Moskowitz CH, Nademanee A, Masszi T, et al. (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385: 1853-62
7. Becker ML, Near R, Mudgett-Hunter M, et al. (1989). Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell 58: 911-21
8. Stancovski I, Schindler DG, Waks T, et al. (1993). Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151: 6577-82
9. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, et al. (2013). Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19: 3153-64
10. Haso W, Lee DW, Shah NN, et al. (2013). Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121: 1165-74
11. Hombach AA, Schildgen V, Heuser C, et al. (2007). T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J. Immunol. 178: 4650-57
12. Savoldo B, Ramos CA, Liu E, et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Investig. 121: 1822-26
13. Hudecek M, Sommermeyer D, Kosasih PL, et al. (2015). The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3: 125-35
14. Irving BA, Weiss A. (1991). The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-Associated signal transduction pathways. Cell 64: 891-901
15. Krause A, Guo HF, Latouche JB, et al. (1998). Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188: 619-26
16. Finney HM, Lawson AD, Bebbington CR, Weir AN. (1998). Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161: 2791-97
17. Pule MA, Straathof KC, Dotti G, et al. (2005). A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 12: 933-41
18. Vera J, Savoldo B, Vigouroux S, et al. (2006). T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108: 3890-97
19. Imai C, Mihara K, Andreansky M, et al. (2004). Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18: 676-84
20. Jakobsen MK, Restifo NP, Cohen PA, et al. (1995). Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J. Immunother. Emphasis Tumor Immunol. 17: 222-28
21. Lou Y, Basha G, Seipp RP, et al. (2008). Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival. Clin. Cancer Res. 14: 1494-501
22. Singh R, Paterson Y. (2007). Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res. 67: 1887-92
23. Vago L, Perna SK, Zanussi M, et al. (2009). Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 361: 478-88
24. Rosenberg SA, Aebersold P, Cornetta K, et al. (1990). Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323: 570-78
25. Varmus H. (1988). Retroviruses. Science 240: 1427-35
26. Geurts AM, Yang Y, Clark KJ, et al. (2003). Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol. Ther. 8: 108-17
27. Wilson MH, Coates CJ, George AL Jr. (2007). PiggyBac transposon-mediated gene transfer in human cells. Mol. Ther. 15: 139-45
28. Gattinoni L, Klebanoff CA, Restifo NP. (2012). Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12: 671-84
29. Restifo NP, Dudley ME, Rosenberg SA. (2012). Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-81
30. Rooney CM, Smith CA, Ng CY, et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-55
31. Hislop AD, Taylor GS, Sauce D, Rickinson AB. (2007). Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25: 587-617
32. Pule MA, Savoldo B, Myers GD, et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14: 1264-70
33. Rischer M, Pscherer S, Duwe S, et al. (2004). Human gammadeltaTcells as mediators of chimaeric-receptor redirected anti-Tumour immunity. Br. J. Haematol. 126: 583-92
34. Imai C, Iwamoto S, Campana D. (2005). Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-83
35. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. (2013). B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19: 2048-60
36. Gottschalk S, Ng CY, Perez M, et al. (2001). An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97: 835-43
37. Yee C, Thompson JA, Byrd D, et al. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. PNAS 99: 16168-73
38. Dunn GP, Old LJ, Schreiber RD. (2004). The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-60
39. Hegde M, Corder A, Chow KK, et al. (2013). Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther. 21: 2087-101
40. Scheuermann RH, Racila E. (1995). CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk. Lymphoma 18: 385-97
41. Davila ML, Riviere I, Wang X, et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6: 224ra25
42. Maude SL, Frey N, Shaw PA, et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371: 1507-17
43. Jensen MC, Popplewell L, Cooper LJ, et al. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 16: 1245-56
44. Antony PA, Piccirillo CA, Akpinarli A, et al. (2005). CD8+ T cell immunity against a tumor/self-Antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-601
45. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. (2005). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-12
46. Kochenderfer JN, Wilson WH, Janik JE, et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099-102
47. Porter DL, Levine BL, Kalos M, et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725-33
48. Williams KM, Hakim FT, Gress RE. (2007). T cell immune reconstitution following lymphodepletion. Semin. Immunol. 19: 318-30
49. Kalos M, Levine BL, Porter DL, et al. 2011.Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3: 95ra73
50. Kochenderfer J, Dudley M, Feldman S, et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-Associated toxicity in a clinical trial of anti-CD19 chimeric-Antigen-receptor-Transduced T cells. Blood 119: 2709-20
51. Kochenderfer JN, Dudley ME, Kassim SH, et al. (2015). Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33: 540-49
52. Brentjens R, Rivière I, Park J, et al. (2011). Safety and persistence of adoptively transferred autologous CD19-Targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-28
53. Cruz CR, Micklethwaite KP, Savoldo B, et al. (2013). Infusion of donor-derived CD19-redirected virusspecific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122: 2965-73
54. Kochenderfer JN, Dudley ME, Carpenter RO, et al. (2013). Donor-derived CD19-TargetedTcells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122: 4129-39
55. Till BG, Jensen MC, Wang J, et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112: 2261-71
56. Ramos C, Ballard B, Liu E, et al. (2015). ChimericTcells for therapy of CD30+Hodgkin and non-Hodgkin lymphomas (HL & NHL). ASCGT Annu. Meet. Abstr. Mol. Ther. 23: Abstr. C-9
57. Ramos CA, Savoldo B, Liu E, et al. (2013). Clinical responses in patients infused with T lymphocytes redirected to target ?-light immunoglobulin chain. ASH Annu. Meet. Abstr. Blood 122: 506
58. Grupp SA, Kalos M, Barrett D, et al. (2013). Chimeric antigen receptor-modifiedTcells for acute lymphoid leukemia. N. Engl. J. Med. 368: 1509-18
59. Brentjens RJ, Riviere I, Park JH, et al. (2011). Safety and persistence of adoptively transferred autologous CD19-Targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-28
60. Kochenderfer JN, Dudley ME, Feldman SA, et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-Associated toxicity in a clinical trial of anti-CD19 chimeric-Antigen-receptortransduced T cells. Blood 119: 2709-20
61. Zhao Y, Moon E, Carpenito C, et al. (2010). Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70: 9053-61
62. Barrett DM, Zhao Y, Liu X, et al. (2011). Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum. Gene Ther. 22: 1575-86
63. Almasbak H, Rian E, Hoel HJ, et al. (2011). Transiently redirected T cells for adoptive transfer. Cytotherapy 13: 629-40
64. Bear AS, Morgan RA, Cornetta K, et al. (2012). Replication-competent retroviruses in gene-modified T cells used in clinical trials: Is it time to revise the testing requirements? Mol. Ther. 20: 246-49
65. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A. (2012). Gene therapy for primary immunodeficiencies: part 1. Curr. Opin. Immunol. 24: 580-84
66. Brenner MK, Rill DR, Moen RC, et al. (1993). Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341: 85-86
67. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. (2013). Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl. Res. 161: 265-83
68. Nakazawa Y, Huye LE, Salsman VS, et al. (2011). PiggyBac-mediated cancer immunotherapy using EBVspecific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol. Ther. 19: 2133-43
69. Di Stasi A, Tey SK, Dotti G, et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365: 1673-83
70. Zhou X, Di Stasi A, Tey SK, et al. (2014). Long-Term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123: 3895-905
71. Ninomiya S, Narala N, Huye L, et al. (2015). Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125: 3905-16
72. Ansell SM, Lesokhin AM, Borrello I, et al. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372: 311-19
73. Li XC, Demirci G, Ferrari-Lacraz S, et al. (2001). IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. 7: 114-18
74. Mueller K, Schweier O, Pircher H. (2008). Efficacy of IL-2-versus IL-15-stimulated CD8 T cells in adoptive immunotherapy. Eur. J. Immunol. 38: 2874-85
75. Ochoa MC, Mazzolini G, Hervas-Stubbs S, et al. (2013). Interleukin-15 in gene therapy of cancer. Curr. Gene Ther. 13: 15-30
76. Hoyos V, Savoldo B, Quintarelli C, et al. (2010). Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24: 1160-70
77. Hsu C, Hughes MS, Zheng Z, et al. (2005). Primary human T lymphocytes engineered with a codonoptimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-Term in the absence of exogenous cytokine. J. Immunol. 175: 7226-34
78. Perna SK, De Angelis B, Pagliara D, et al. (2013). Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin. Cancer Res. 19: 106-17
79. Quintarelli C, Vera JF, Savoldo B, et al. (2007). Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110: 2793-802
80. Brentjens RJ, Latouche JB, Santos E, et al. (2003). Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9: 279-86
81. Klebanoff CA, Finkelstein SE, Surman DR, et al. (2004). IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. PNAS 101: 1969-74
82. Akhurst RJ. (2004). TGF beta signaling in health and disease. Nat. Genet. 36: 790-92
83. Thomas DA, Massague J. (2005). TGF-beta directly targets cytotoxicTcell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-80
84. Bollard CM, Rossig C, Calonge MJ, et al. (2002). Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99: 3179-87
85. Bollard CM, Dotti G, Gottschalk S, et al. (2010). Administration of tumor-specific cytotoxicTlymphocytes engineered to resist TGF-βto patients with EBV-Associated lymphomas. ASH Annu. Meet. Abstr. Blood 116: 560
86. Cirri P, Chiarugi P. (2011). Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res. 1: 482-97
87. Kakarla S, Song XT, Gottschalk S. (2012). Cancer-Associated fibroblasts as targets for immunotherapy. Immunotherapy 4: 1129-38
88. Marx J. (2008). Cancer biology. All in the stroma: cancer's Cosa Nostra. Science 320: 38-41
89. Mueller MM, Fusenig NE. (2004). Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4: 839-49
90. National Cancer Institute. (2014). Anti-CD22 chimeric receptor T cells in pediatric and young adults with recurrent or refractory CD22-expressing B cell malignancies. ClinicalTrials.gov, Bethesda, MD, Natl. Libr. Med. http://clinicaltrials.gov/show/NCT02315612
91. MD Anderson Cancer Center, CLL Global Research Foundation Alliance. (2014). Autologous ROR1RCAR-T cells for chronic lymphocytic leukemia (CLL). ClinicalTrials.gov, Bethesda, MD, Natl. Libr. Med. http://clinicaltrials.gov/show/NCT02194374
92. Cruz CR, Micklethwaite KP, Savoldo B, et al. (2013). Infusion of donor-derived CD19-redirected-virusspecific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study. Blood 122: 2965-73
93. Kochenderfer J, Dudley M, Carpenter R, et al. (2013). Donor-derived CD19-Targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122: 4129-39